Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
about
Plasma levels of the pro-inflammatory protein S100A12 (EN-RAGE) are associated with muscle and fat mass in hemodialysis patients: a cross-sectional study.Correlations of MTHFR 677C>T polymorphism with cardiovascular disease in patients with end-stage renal disease: a meta-analysis.S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent mannerPlacental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group boPrognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan.S100/calgranulins EN-RAGEing the blood vessels: implications for inflammatory responses and atherosclerosisChronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23.Plasma S100A12 levels and peripheral arterial disease in end-stage renal diseaseThe receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study.Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis PatientsWhole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial.S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets.Mechanisms and treatment of extraosseous calcification in chronic kidney disease.The role of damage- and pathogen-associated molecular patterns in inflammation-mediated vulnerability of atherosclerotic plaques.Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.Common Aging Signature in the Peripheral Blood of Vascular Dementia and Alzheimer's Disease.High-Flux Dialysis: Clinical, Biochemical, and Proteomic Comparison with Low-Flux Dialysis and On-Line Hemodiafiltration.Potential effects of calcium binding protein S100A12 on severity evaluation and curative effect of severe acute pancreatitis.Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.S100A12 concentrations and myeloperoxidase activities are increased in the intestinal mucosa of dogs with chronic enteropathies.Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
P2860
Q33723012-CDB0A391-5D96-45A1-932E-6C521B89EF81Q33933333-79D69490-5A9D-4989-9FF1-5F796BA58F1FQ33939707-9D75042B-53CC-44DA-91E3-048AF45C6A3CQ34493096-0595D39C-2511-4D0E-9D1E-817A0FD3F101Q34549739-8EAF4B21-9197-45E5-9891-206A40614B88Q35627729-B49C2F16-0401-4C20-B1BC-E3081D730FDFQ35737906-41F25C31-C94E-494E-8870-8B6AE81D4702Q35791729-85F16898-FFA5-4D52-9F1D-102948466E0CQ35896110-9642F580-8527-486C-8F2D-5C2847807812Q35935760-E0E39F88-AF0A-4538-B21B-5977AB9CEF5CQ35951916-CEB02FAC-60B8-4180-94C2-BAA3EABAB79AQ36631781-BAE9B535-3403-4CF9-94DF-7E588B7CC91AQ37902504-4F2DEB9F-087C-4276-92CE-45D16DD88CE2Q39459619-A62C49F3-02A1-4A04-AE44-C54503E8DFE6Q40443709-A3B3753E-388E-4C06-A06C-8005D007B1E7Q44131522-1A38E32E-23C7-413D-80F8-07A20075B4EEQ48115931-ED214765-7838-4598-96F2-FF9DF32043EEQ50965083-E1247211-C2F7-48B4-913F-1D06BEE57F61Q51110150-E16E41E8-4CA0-4981-A2B9-87816AB667F7Q54764181-311BE5D5-8CC5-4D54-B9F2-75792DD2B14AQ55434420-27A7AB54-2C52-47CC-8A42-7D76C3BFCB81Q55474587-4462BA51-6E2A-4FCA-800C-0FA88EE74C10
P2860
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@ast
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@en
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@nl
type
label
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@ast
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@en
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@nl
prefLabel
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@ast
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@en
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients.
@nl
P2093
P2860
P356
P1476
Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients
@en
P2093
Atsushi Kosaki
Chikako Sakoda
Eiko Matsuoka
Hiroaki Matsubara
Kumiko Iida
Masato Nishimura
Noboru Maki
Noriko Kishimoto
Noriyuki Iwamoto
Toshihiko Ono
P2860
P304
P356
10.2215/CJN.08310910
P577
2011-01-21T00:00:00Z